Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 07/14/14 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | |
| 07/14/14 | UPLOAD | SEC-generated letter |
|
1 | |
| 07/11/14 | UPLOAD | SEC-generated letter |
|
2 | |
| 07/10/14 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
   |
66 |
| 07/02/14 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
26 | |
| 06/12/14 | 5 | Annual statement of changes in beneficial ownership of securities |
|
2 | |
| 06/02/14 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 06/02/14 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 06/02/14 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 06/02/14 | 4 | Statement of changes in beneficial ownership of securities |
|
2 |
